"Skin and skin structure infection" from_date:2012

Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections Evidence summary Published: 11 May 2022 www.nice.org.uk/guidance/es39 Product overview The content of this evidence summary was up to date in February 2022. See summaries of product characteristics (SPCs ), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information. Oritavancin (Tenkasi, Menarini) is a glycopeptide antibiotic given intravenously as a single dose. It has a marketing authorisation for treating acute bacterial skin and skin structure infections (ABSSSI) in adults. © NICE 2023. All rights reserved. Subject

Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections Evidence summary Published: 5 January 2021 www.nice.org.uk/guidance/es32 pathwaysProduct overview Product overview The content of this evidence summary was up to date in December 2020. See summaries of product characteristics, British National Formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or the NICE websites for up-to-date information. Delafloxacin (Quofenix, Menarini) is a fluoroquinolone antibiotic, which is available as a powder for infusion and a tablet. It has a marketing authorisation for treating acute bacterial skin and skin structure infections (ABSSSI) in adults when

Tedizolid phosphate (Sivextro) - acute bacterial skin and skin structure infections (ABSSSI) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology

Dalbavancin (Xydalba) - Acute bacterial skin and skin structure infections Return to Article DetailsDalbavancin (Xydalba)

Dalbavancin (Xydalba) - Acute bacterial skin and skin structure infections Return to Article DetailsDalbavancin (Xydalba)

Oritavancin (Tenkasi) - treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults 1 Published 09 May 2022 1 SMC2285 oritavancin 400mg powder for concentrate for solution for infusion (Tenkasi®) Menarini International Operations Luxembourg S.A. 04 September 2020 (Issued 08 April 2022) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a resubmission oritavancin (Tenkasi®) is accepted for restricted use within NHSScotland. Indication under review: treatment of acute bacterial skin and skin structure infections (ABSSSI

Delafloxacin (Quofenix) - treatment of acute bacterial skin and skin structure infections (ABSSSI) 1 Published 11 July 2022 1 SMC2453 delafloxacin 450mg tablets and 300mg powder for concentrate for solution for infusion (Quofenix®) A. Menarini Farmaceutica Internazionale SRL 10 June 2022 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission delafloxacin (Quofenix ®) is accepted for restricted use within NHSScotland. Indication under review: treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when

Delafloxacin (Quofenix) - for the treatment of acute bacterial skin and skin structure infections (ABSSSI) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics

Dalbavancin (Xydalba) - for the treatment of adult patients with acute bacterial skin and skin structure infections Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health

Ceftobiprole medocaril for skin and skin-structure infections. On 3 April 2024, the United States Food and Drug Administration (FDA) approved ceftobiprole medocaril sodium (Zevtera) for injection for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) as well as patients with Staphylococcus aureus bloodstream infections and patients 3 months to less than 18

Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections. Lefamulin is a pleuromutilin antibiotic approved for the treatment of community-acquired bacterial pneumonia (CABP). Its spectrum of activity, good penetration into soft tissues and low rates of cross-resistance also make lefamulin a potentially valuable option for treatment of acute bacterial skin and skin structure infections (ABSSSIs). A Phase 2 trial of lefamulin for ABSSSI indicated similar efficacy of 100 and 150 mg q12h IV dosing regimens. In the present study, the potential of lefamulin for this indication was further evaluated from a translational pharmacokinetic/pharmacodynamic perspective. PTA was determined for various dosages using Monte Carlo simulations of a population

Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections. Pharmacokinetic-pharmacodynamic (PK-PD) relationships for efficacy were evaluated using data from omadacycline-treated patients with acute bacterial skin and skin structure infections (ABSSSI) enrolled in two phase 3

Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings. A pathway for the treatment of acute bacterial skin and skin structure infections (ABSSSI) with a single intravenous (IV) dose of dalbavancin was previously shown to reduce hospital admissions and shorten

Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA. The population pharmacokinetics/pharmacodynamics (PK/PD) of minocycline, rifampicin and linezolid in patients with complicated skin and soft tissue infections (cSSTIs) caused by MRSA are described. Samples were collected in a Phase 4 study

Omadacycline (Nuzyra) - To treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections Drug Approval Package: NUZYRA * Skip to main page content * Skip to search * Skip to topics menu * Skip to common linksHHS U.S. Department of Health and Human Services U.S. Food and Drug Administration * Follow FDA * En EspañolSearch FDASubmit search * Popular Content

Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019). Tedizolid was approved by the United States Food and Drug Administration to treat acute bacterial skin and skin structure infections in adults in 2014, and in 2020, United States Food and Drug Administration expanded the approval of tedizolid to treat pediatric patients 12 years of age and older. This study assessed the activity of tedizolid and comparator agents against clinical surveillance isolates collected from pediatric patients with skin and skin structure infection in the United States. A total of 2747 gram-positive organisms (1 per patient) were collected in 2015 to 2019 from pediatric (≤17 years old) patients

The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections. Acute bacterial skin and skin structure infections (ABSSSIs) are a significant source of morbidity in children. Dalbavancin, approved for the treatment of adults and children with ABSSSI, has a well-established safety profile in adults. We report safety

Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: The AIDA open label, randomized, controlled Phase 4 trial. The need for oral, cost-effective treatment for complicated skin and skin structure infections (cSSSIs) due to methicillin-resistant (MRSA) was addressed by the non-inferiority

Dalbavancin (Xydalba) - treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults

Diabetes and acute bacterial skin and skin structure infections. Acute bacterial skin and skin structures infections (ABSSSIs) are associated with high morbidity, costs and mortality in patients with diabetes mellitus. Their appropriate management should include several figures and a well-organized approach. This review aims to highlight the interplay between diabetes and ABSSSIs and bring out